Abstract: Idiopathic thrombocytopenic purpura (ITP) is the most common clinically acquired bleeding disorder, characterized by thrombocytopenia, increased or normal bone marrow megakaryocyte counts with maturation disorders, which the International Organization of Hematological Diseases (IOHD) has preferred to refer to as immune thrombocytopenia in recent years. Approximately 80-90% of patients recover within 6 months of diagnosis, while 10-20% have a chronic course, of which refractory ITP is known as refractory ITP if regular glucocorticosteroids, splenectomy, and general immunosuppressive therapy are ineffective.